Feature|Articles|April 17, 2024
- Pharmaceutical Executive: April 2024
- Volume 44
- Issue 4
Pharmaceutical Executive: April 2024 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive April 2024 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 2 years ago
Power in Partneringalmost 2 years ago
The IRA Impact: Navigating Its Evolving Complexitiesalmost 2 years ago
Fighting for Innovationalmost 2 years ago
Say Hello to Flexible: Reimagining the Patient Journeyalmost 2 years ago
Aspiring for the C-Suite? Consider Being a Chief of Staffalmost 2 years ago
Latent Benefit of Access Restrictions for Rare Conditionsalmost 2 years ago
The Biotech Rally has Legs—But Rising Tide Isn’t Lifting All Boatsalmost 2 years ago
The Pharmaceutical Playbook for Asia’s Private Marketalmost 2 years ago
Operating Models for Successful DOL EngagementNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Your Phase III Clinical Protocol Is Your Initial Product Launch
2
Pharmaceutical Executive Daily: Public Citizen Sues The Trump Administration Over Undisclosed Drug Price Agreements
3
Taking Advantage of ‘Hidden Gem’ Talent Hubs
4
AstraZeneca Enters $4.7 Billion Collaboration Agreement with CSPC Pharmaceuticals
5

